Neurostimulation for cognitive enhancement in Alzheimer's disease (the NICE-AD study): a randomized clinical trial.
Neurodegener Dis Manag
; 11(4): 277-288, 2021 08.
Article
in En
| MEDLINE
| ID: mdl-34240627
ABSTRACT
New therapies for symptoms in Alzheimer's disease (AD) are urgently needed. Prior studies suggest that transcranial direct current stimulation (tDCS), a noninvasive neuromodulatory method, may be a safe and potentially effective treatment, but conclusions have been limited by small-sample sizes and brief stimulation protocols. This double-blind randomized trial involving 100 older adults with mild-to-moderate AD examines effects of 6 months of at-home active tDCS or sham delivered over the dorsolateral prefrontal cortex. The primary outcome is global cognitive performance. Secondary outcomes include executive-control/spatial selective attention, functional neuroplasticity, depressive symptoms, quality of life and the durability of effects 3 months after the stimulation period. The results will provide evidence on the efficacy of multimonth at-home tDCS in the AD treatment. =Clinical trial identifier NCT04404153 (Clinicaltrials.gov).
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Cognition
/
Alzheimer Disease
/
Transcranial Direct Current Stimulation
Type of study:
Clinical_trials
/
Guideline
Aspects:
Patient_preference
Limits:
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Neurodegener Dis Manag
Year:
2021
Document type:
Article
Affiliation country:
United States